Alberto M Marra1, Benjamin Egenlauf2, Nicola Ehlken2, Christine Fischer3, Christina Eichstaedt2, Christian Nagel2, Eduardo Bossone4, Antonio Cittadini5, Michael Halank6, Henning Gall7, Karen M Olsson8, Tobias J Lange9, Ekkehard Grünig10. 1. Pulmonary Hypertension Center, Thoraxclinic at the University of Heidelberg, Germany; Internal Medicine Section-Department of Translational Medical Sciences, "Federico II" University School of Medicine, Naples, Italy. 2. Pulmonary Hypertension Center, Thoraxclinic at the University of Heidelberg, Germany. 3. Institute of Human Genetics, University Hospital Heidelberg, Germany. 4. Cardiology Division, "Cava de' Tirreni and Amalfi Coast" Hospital, Heart Dept., University of Salerno - Italy and Cardiac Surgery Dept., IRCCS Policlinico San Donato, Milan, Italy. 5. Internal Medicine Section-Department of Translational Medical Sciences, "Federico II" University School of Medicine, Naples, Italy. 6. Medical Clinic I, University Hospital of TU Dresden, Germany. 7. Department of Pneumology, University of Gießen Lung Center, Germany. 8. Department of Respiratory Medicine, Hannover Medical School, Germany. 9. Internal Medicine II, University Medical Center Würzburg, Germany. 10. Pulmonary Hypertension Center, Thoraxclinic at the University of Heidelberg, Germany. Electronic address: ekkehard.gruenig@med.uni-heidelberg.de.
Abstract
BACKGROUND: Riociguat is a soluble guanylate cyclase stimulator approved for pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH). The objective of this study was to evaluate the change of right heart size and function assessed by echocardiography during long-term treatment with riociguat. METHODS: We assessed patients who started riociguat treatment (1.0-2.5mg tid) within the trials PATENT, PATENTplus, EAS and CHEST and continued for 3-12 months. Echocardiography, 6-minute walking distance (6MWD) and further clinical parameters were analyzed at baseline, after 3, 6 and 12 months. Right heart catheterization was performed at baseline and after 3 months. For missing data we performed the last and baseline observation carried forward (LOCF, BOCF) method as sensitivity analyses. RESULTS: Thirty-nine patients (21 PAH, 18 CTEPH, mean pulmonary arterial pressure 43 ± 2 mmHg, PVR 600 ± 43 dyn ∗ s ∗ cm(-5), 56.4% treatment-naïve) were included. Mean right ventricular (RV) area significantly decreased after 3 (-2.1 ± 3.9 cm(2), equals -7.4 ± 15.3%, p = 0.002), 6 (-4.2 ± 3.2 cm(2), equals -16.1 ± 11.5%, p < 0.001) and 12 months (-5.9 ± 4.6 cm(2), equals -22.1 ± 14.2%, p < 0.001) compared to baseline. Right atrial area significantly decreased after 12 months (-3.5 ± 4.1cm(2), equals -16.8 ± 19.2%, p < 0.001) and TAPSE significantly improved after 6 (+ 2 ± 4.7, equals 12 ± 25.8%, p = 0.025) and 12 months (+ 3.6 ± 5.4, equals 21.0 ± 29.6%, p = 0.002). Furthermore, RV wall thickness and 6MWD significantly improved after 3, 6 and 12 months (p < 0.05). Invasive hemodynamics significantly improved after 3 months. Both LOCF and BOCF showed similar significance and lower effect sizes. CONCLUSION: Long-term treatment with riociguat significantly reduced right heart size and improved RV function in PAH and CTEPH. Further prospective studies are needed to confirm these results.
BACKGROUND:Riociguat is a soluble guanylate cyclase stimulator approved for pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH). The objective of this study was to evaluate the change of right heart size and function assessed by echocardiography during long-term treatment with riociguat. METHODS: We assessed patients who started riociguat treatment (1.0-2.5mg tid) within the trials PATENT, PATENTplus, EAS and CHEST and continued for 3-12 months. Echocardiography, 6-minute walking distance (6MWD) and further clinical parameters were analyzed at baseline, after 3, 6 and 12 months. Right heart catheterization was performed at baseline and after 3 months. For missing data we performed the last and baseline observation carried forward (LOCF, BOCF) method as sensitivity analyses. RESULTS: Thirty-nine patients (21 PAH, 18 CTEPH, mean pulmonary arterial pressure 43 ± 2 mmHg, PVR 600 ± 43 dyn ∗ s ∗ cm(-5), 56.4% treatment-naïve) were included. Mean right ventricular (RV) area significantly decreased after 3 (-2.1 ± 3.9 cm(2), equals -7.4 ± 15.3%, p = 0.002), 6 (-4.2 ± 3.2 cm(2), equals -16.1 ± 11.5%, p < 0.001) and 12 months (-5.9 ± 4.6 cm(2), equals -22.1 ± 14.2%, p < 0.001) compared to baseline. Right atrial area significantly decreased after 12 months (-3.5 ± 4.1cm(2), equals -16.8 ± 19.2%, p < 0.001) and TAPSE significantly improved after 6 (+ 2 ± 4.7, equals 12 ± 25.8%, p = 0.025) and 12 months (+ 3.6 ± 5.4, equals 21.0 ± 29.6%, p = 0.002). Furthermore, RV wall thickness and 6MWD significantly improved after 3, 6 and 12 months (p < 0.05). Invasive hemodynamics significantly improved after 3 months. Both LOCF and BOCF showed similar significance and lower effect sizes. CONCLUSION: Long-term treatment with riociguat significantly reduced right heart size and improved RV function in PAH and CTEPH. Further prospective studies are needed to confirm these results.
Authors: Alberto Maria Marra; Marco Proietti; Eduardo Bossone; Andrea Salzano; Antonio Cittadini Journal: Intern Emerg Med Date: 2019-06-18 Impact factor: 3.397
Authors: Christian Schoenfeld; Jan B Hinrichs; Karen M Olsson; Martin-Alexander Kuettner; Julius Renne; Till Kaireit; Christoph Czerner; Frank Wacker; Marius M Hoeper; Bernhard C Meyer; Jens Vogel-Claussen Journal: Eur Radiol Date: 2018-10-11 Impact factor: 5.315
Authors: Martin Koestenberger; Ante Burmas; William Ravekes; Alexander Avian; Andreas Gamillscheg; Gernot Grangl; Marlene Grillitsch; Georg Hansmann Journal: Pediatr Cardiol Date: 2015-12-26 Impact factor: 1.655
Authors: Tommaso Vezzosi; Oriol Domenech; Giulia Costa; Federica Marchesotti; Luigi Venco; Eric Zini; Maria Josefa Fernández Del Palacio; Rosalba Tognetti Journal: J Vet Intern Med Date: 2018-09-14 Impact factor: 3.333